Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25890823 | 0.85 | HSD17B10 (0.34) | OPRD1HSD17B10P2RY6 | |
| SCHEMBL22606701 | 0.80 | HSD17B10 (0.33) | OPRD1HSD17B10 | |
| SCHEMBL1230833 | 0.76 | HSD17B10 (0.39) | OPRD1HSD17B10P2RY6 | |
| SCHEMBL1149469 | 0.75 | P2RY6 (0.42) | OPRD1HSD17B10P2RY6 | |
| SCHEMBL5968018 | 0.75 | P2RY6 (0.40) | OPRD1HSD17B10P2RY6 | |
| SCHEMBL7209073 | 0.75 | HSD17B10 (0.36) | OPRD1HSD17B10P2RY6 | |
| SCHEMBL12847616 | 0.71 | HSD17B10 (0.38) | OPRD1HSD17B10P2RY6 | |
| SCHEMBL6550277 | 0.71 | HSD17B10 (0.39) | OPRD1HSD17B10P2RY6 | |
| SCHEMBL6757638 | 0.71 | HSD17B10 (0.39) | OPRD1HSD17B10P2RY6 | |
| SCHEMBL141450 | 0.71 | HSD17B10 (0.39) | OPRD1HSD17B10P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0777498-B1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | DCLRE1B, RNASE1, DCLRE1A | OPRD1 4714/4885HSD17B10 3614/4885P2RY6 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.